Skip to main content
main-content

09.12.2017 | Head and Neck | Ausgabe 2/2018

European Archives of Oto-Rhino-Laryngology 2/2018

Identification of human papillomavirus (HPV) subtype in oral cancer patients through microarray technology

Zeitschrift:
European Archives of Oto-Rhino-Laryngology > Ausgabe 2/2018
Autoren:
Soung Min Kim, Ik Jae Kwon, Hoon Myoung, Jong Ho Lee, Suk Keun Lee
Wichtige Hinweise
Soung Min Kim and Ik Jae Kwon equal co-first authors.

Abstract

Purpose

Human papilloma virus (HPV) is the main source of cervical cancer. Many recent studies have revealed the prevalence and prognosis of HPV associated with oropharyngeal squamous cell carcinoma, but fewer reports have evaluated HPV in oral squamous cell carcinoma (OSCC). The purpose of this study was to determine the prevalence and prognosis of HPV associated with OSCC according to HPV and tumor types.

Materials and methods

We used a DNA chip kit (MY-HPV chip kit ®, Mygene Co., Korea) to detect high-risk HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, 58) and low-risk subtypes (6, 11, 34, 40, 42, 43, 44) among 187 patients. The prevalence was determined by Chi-square and Fisher’s exact tests, and the prognosis was calculated by the Kaplan–Meier method and the log-rank test.

Results

The overall prevalence of HPV in OSCC was 7.0% for all HPV positives and 4.3% for high-risk HPV positives. The prevalence of HPV was significantly higher in individuals under 65 years old and in those with tumors in the tongue and gum regions. The prognosis did not differ between the HPV-positive and -negative groups. Although the prevalence of HPV-positive cases in OSCC was low (7.0, 4.3%) and the prognosis did not depend on HPV positivity, HPV-associated OSCC should be considered in the evaluation and treatment of oral cancer patients. In addition, separating high- and low-risk groups based on the HPV status of other body parts might not be appropriate.

Discussion

The DNA microarray method can accurately detect known HPV subtypes simultaneously, but has limitations in detecting new subtypes. Vaccines can also be used to prevent HPV-associated OSCC in patients, so further studies on the prognosis and efficacy of vaccines should be undertaken.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Bis zum 22.10. bestellen und 100 € sparen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

European Archives of Oto-Rhino-Laryngology 2/2018 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet HNO

15.10.2018 | Neues aus der Industrie | Onlineartikel

Rationaler Antibiotikaeinsatz in Klinik und Praxis

11.10.2018 | DAK 2018 | Kongressbericht | Nachrichten

Akupunktur bei allergischen Erkrankungen

11.10.2018 | DAK 2018 | Kongressbericht | Nachrichten

Personalisierte Prävention im Jahr 2030 möglich?

 

 

 
 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise